Literature DB >> 19103649

Calcineurin inhibition in splenocytes induced by pavlovian conditioning.

Gustavo Pacheco-López1, Carsten Riether, Raphael Doenlen, Harald Engler, Maj-Britt Niemi, Andrea Engler, Annemieke Kavelaars, Cobi J Heijnen, Manfred Schedlowski.   

Abstract

Pavlovian conditioning is one of the major neurobiological mechanisms of placebo effects, potentially influencing the course of specific diseases and the response to a pharmacological therapy, such as immunosuppression. In our study with behaviorally conditioned rats, a relevant taste (0.2% saccharin) preceded the application of the immunosuppressive drug cyclosporin A (CsA), a specific calcineurin (CaN) inhibitor. Our results demonstrate that through pavlovian conditioning the particular pharmacological properties of CsA can be transferred to a neutral taste, i.e., CaN activity was inhibited in splenocytes from conditioned rats after reexposure to the gustatory stimulus. Concomitant immune consequences were observed on ex vivo mitogenic challenge (anti-CD3). Particularly, Th1-cytokine, but not Th2-cytokine, production and cell proliferation were impeded. Appropriate pharmacological and behavioral controls certify that all these changes in T-lymphocyte reactivity are attributable to mere taste reexposure. Furthermore, the underlying sympathetic-lymphocyte interaction was revealed modeling the conditioned response in vitro. CaN activity in CD4(+) T lymphocytes is reduced by beta-adrenergic stimulation (terbutaline), with these effects antagonized by the beta-adrenoreceptor antagonist nadolol. In summary, CaN was identified as the intracellular target for inducing conditioned immunosuppression by CsA, contributing to our understanding of the intracellular mechanisms behind "learned placebo effects."

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19103649     DOI: 10.1096/fj.08-115683

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

Review 1.  The placebo effect: advances from different methodological approaches.

Authors:  Karin Meissner; Ulrike Bingel; Luana Colloca; Tor D Wager; Alison Watson; Magne Arve Flaten
Journal:  J Neurosci       Date:  2011-11-09       Impact factor: 6.167

2.  The Placebo Effect in Pain Therapies.

Authors:  Luana Colloca
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-09-14       Impact factor: 13.820

Review 3.  Placebo mechanisms across different conditions: from the clinical setting to physical performance.

Authors:  Antonella Pollo; Elisa Carlino; Fabrizio Benedetti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-06-27       Impact factor: 6.237

Review 4.  Role of placebo effects in pain and neuropsychiatric disorders.

Authors:  Annabelle M Belcher; Sergi Ferré; Pedro E Martinez; Luana Colloca
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-06-14       Impact factor: 5.067

5.  Electrical activity in rat cortico-limbic structures after single or repeated administration of lipopolysaccharide or staphylococcal enterotoxin B.

Authors:  Raphael Doenlen; Ute Krügel; Timo Wirth; Carsten Riether; Andrea Engler; Geraldine Prager; Harald Engler; Manfred Schedlowski; Gustavo Pacheco-López
Journal:  Proc Biol Sci       Date:  2010-11-24       Impact factor: 5.349

Review 6.  Contributions of the adaptive immune system to mood regulation: Mechanisms and pathways of neuroimmune interactions.

Authors:  Miles Herkenham; Stacey L Kigar
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-09-06       Impact factor: 5.067

Review 7.  Learned immunosuppression: extinction, renewal, and the challenge of reconsolidation.

Authors:  Martin Hadamitzky; Harald Engler; Manfred Schedlowski
Journal:  J Neuroimmune Pharmacol       Date:  2012-07-13       Impact factor: 4.147

8.  Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance.

Authors:  Rosanne M Smits; Dieuwke S Veldhuijzen; Henriet van Middendorp; Petra C E Hissink Muller; Wineke Armbrust; Elizabeth Legger; Nico M Wulffraat; Andrea W M Evers
Journal:  Pediatr Rheumatol Online J       Date:  2020-02-07       Impact factor: 3.054

Review 9.  Relieving pain using dose-extending placebos: a scoping review.

Authors:  Luana Colloca; Paul Enck; David DeGrazia
Journal:  Pain       Date:  2016-08       Impact factor: 7.926

10.  Learned immunosuppressive placebo responses in renal transplant patients.

Authors:  Julia Kirchhof; Liubov Petrakova; Alexandra Brinkhoff; Sven Benson; Justine Schmidt; Maike Unteroberdörster; Benjamin Wilde; Ted J Kaptchuk; Oliver Witzke; Manfred Schedlowski
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-02       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.